Although our results are highly consistent with prior work reporting preferential vulnerability of KRAS- or BRAF-mutant CRC cells to furin depletion [22], validation in BRAF-mutant and wild-type models will be essential to fully define the molecular dependency. This evidence concerns the gene KRAS and colorectal carcinoma.